FBIO Fortress Biotech, Inc.

3.26
+0  (2%)
Previous Close 3.21
Open 3.24
Price To book 4.08
Market Cap 164.04M
Shares 50,319,000
Volume 74,978
Short Ratio 21.63
Av. Daily Volume 154,556

SEC filingsSee all SEC filings

  1. D - Notice of Exempt Offering of Securities 17769621
  2. 8-K - Current report 17746794
  3. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17695336
  4. 8-K - Current report 17695139
  5. 8-K - Current report 17655285

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data in adults due 1H 2019.
CEVA101
Severe Traumatic Brain Injury
Phase 2 data in children due 1H 2018.
CEVA101
Severe Traumatic Brain Injury
Phase 2 data due 1H 2018.
Pepvax vaccine
Cytomegalovirus (CMV)
Phase 1/2 initiated October 2016.
CK‐101
Solid tumors - cancer
Phase 2 trial ongoing with Phase 3 to be initiated in 2017.
N-acetyl-D-mannosamine (ManNAc)
GNE Myopathy
Phase 3 to be initiated in 2017 with data due in 2018.
IV Tramadol
Post-operative Pain
Phase 2 data due 2H 2017.
Triplex vaccine
Cytomegalovirus (CMV)

Latest News

  1. Fortress Biotech Announces Orphan Drug Designations for CAEL-101 in Amyloidosis
  2. Checkpoint Therapeutics Reports Preclinical Data for Two Oncology Programs
  3. Fortress Biotech to Present at BioCentury’s 24th Annual Future Leaders in the Biotech Industry Conference
  4. ETFs with exposure to Fortress Biotech, Inc. : March 30, 2017
  5. Fortress Biotech, Inc. :FBIO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  6. Fortress Biotech (FBIO) Catches Eye: Stock Moves Up 8.3%
  7. Checkpoint Therapeutics to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2017
  8. Fortress Biotech Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2016
  9. Fortress Biotech Forms New Subsidiary, Cyprium Therapeutics, Inc., to Develop Novel Therapies for Menkes Disease and Related Copper Metabolism Disorders
  10. Fortress Biotech to Present at the 29th Annual ROTH Conference
  11. Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lung Cancer Compound CK-101
  12. National Holdings’ OPN Capital Markets Closes $94.5 Million Private Placement Financing for Mustang Bio, Inc., a Subsidiary of Fortress Biotech
  13. Fortress Biotech Announces that its Subsidiary, Mustang Bio, Closes $94.5 Million Private Placement Financing
  14. Fortress Biotech (FBIO) in Focus: Stock Moves 20.9% Higher
  15. ETFs with exposure to Fortress Biotech, Inc. : December 29, 2016
  16. Fortress Biotech Inc (FBIO) Spike: Is It Deserved, And What’s Next?

SEC Filings

  1. D - Notice of Exempt Offering of Securities 17769621
  2. 8-K - Current report 17746794
  3. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17695336
  4. 8-K - Current report 17695139
  5. 8-K - Current report 17655285
  6. 8-K - Current report 17648217
  7. 8-K - Current report 17605782
  8. 8-K - Current report 17576415
  9. SC 13D/A (Amend) - General statement of acquisition of beneficial ownership 17554408
  10. SC 13D/A (Amend) - General statement of acquisition of beneficial ownership 17554327